Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 1 |
2012 | 1 |
2014 | 1 |
2015 | 1 |
2016 | 1 |
2017 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development.
Expert Opin Investig Drugs. 2017 Feb;26(2):155-160. doi: 10.1080/13543784.2017.1275562. Epub 2017 Jan 2.
Expert Opin Investig Drugs. 2017.
PMID: 28001096
Review.
To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from inactive conformation using molecular dynamic simulations.
Dean E, Kumar V, McConnell A, Pagnoncelli IB, Wu C.
Dean E, et al.
J Biomol Struct Dyn. 2023 Aug-Sep;41(13):6359-6376. doi: 10.1080/07391102.2022.2107074. Epub 2022 Aug 8.
J Biomol Struct Dyn. 2023.
PMID: 35938617
Item in Clipboard
Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures.
Chung PC, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E, Befort K, Kieffer BL.
Chung PC, et al.
Behav Brain Res. 2015 Feb 1;278:429-34. doi: 10.1016/j.bbr.2014.10.029. Epub 2014 Oct 30.
Behav Brain Res. 2015.
PMID: 25447299
Free PMC article.
Item in Clipboard
δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization.
Nozaki C, Le Bourdonnec B, Reiss D, Windh RT, Little PJ, Dolle RE, Kieffer BL, Gavériaux-Ruff C.
Nozaki C, et al.
J Pharmacol Exp Ther. 2012 Sep;342(3):799-807. doi: 10.1124/jpet.111.188987. Epub 2012 Jun 13.
J Pharmacol Exp Ther. 2012.
PMID: 22700431
Free PMC article.
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5747) are novel delta-opioi …
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl …
Item in Clipboard
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE.
Le Bourdonnec B, et al.
J Med Chem. 2008 Oct 9;51(19):5893-6. doi: 10.1021/jm8008986. Epub 2008 Sep 13.
J Med Chem. 2008.
PMID: 18788723
Item in Clipboard
Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test.
Huang P, Tunis J, Parry C, Tallarida R, Liu-Chen LY.
Huang P, et al.
Eur J Pharmacol. 2016 Jun 15;781:53-9. doi: 10.1016/j.ejphar.2016.03.061. Epub 2016 Apr 1.
Eur J Pharmacol. 2016.
PMID: 27044434
Free PMC article.
Item in Clipboard
Cite
Cite